How Much Does Letybo Cost Compared With Botox? A Complete Guide to Price, Units, Dosing, Duration and Value

Letybo may cost less than Botox at some aesthetic practices, but there is no scientifically valid way to determine which product is cheaper simply by comparing the advertised price per Unit. Letybo and Botox use product-specific potency assays, and the FDA states that their Units cannot be directly compared or converted. A meaningful comparison should instead consider the total treatment price, treatment areas, product-specific dosing, expected duration, frequency of retreatment, provider expertise and the patient’s individual treatment goals.

That distinction is particularly important when comparing Letybo and Botox because both are botulinum toxin type A products, but their labeled doses and Units are not interchangeable.

At a Glance: Letybo vs. Botox Cost and Value

The FDA labeling for both products specifically cautions against treating their Units as interchangeable.

Is Letybo Cheaper Than Botox?

Sometimes; but the answer is more complicated than the advertised price.

Some practices may charge less for Letybo than for Botox. Others may charge approximately the same amount, and some may charge more.

There is no universal national price for either product.

Aesthetic injectable pricing can vary according to:

• Geographic location
• Provider experience
• Practice overhead
• Treatment area
• Amount of product used
• Pricing model
• Promotions
• Membership programs
• Consultation policies
• Follow-up policies
• Number of areas treated

Therefore, the statement:

“Letybo is cheaper than Botox.” is too broad to be medically or economically useful.

A more accurate statement is:

Letybo may be less expensive than Botox at some practices, but the relative cost varies and cannot be determined simply by comparing price per Unit.

Why Is Comparing Letybo and Botox by Unit Price Misleading?

This is probably the single most important thing for patients to understand when comparing these two products.

Letybo is supplied in Units, and Botox is also supplied in Units.

That does not mean the Units have the same biological meaning.

The FDA states that Letybo’s potency Units are specific to its preparation and assay and are not interchangeable with Units of other botulinum toxin products.

The Botox Cosmetic prescribing information makes the same fundamental point from the opposite direction: Botox Units are specific to the Botox preparation and assay and cannot be compared with or converted into Units of another botulinum toxin product.

Therefore:

10 Letybo Units cannot simply be assumed to equal 10 Botox Units.

And:

20 Letybo Units cannot simply be assumed to equal 20 Botox Units.

This is why a “$X per Unit” advertisement does not, by itself, tell you which treatment is cheaper.

Does 20 Units of Letybo Equal 20 Units of Botox?

No.

This is one of the most common questions patients ask.

Letybo’s FDA-labeled dose for glabellar lines is 20 Units, administered as 4 Units into each of five injection sites.

Botox Cosmetic’s FDA-labeled dose for glabellar lines is also 20 Units.

But the fact that both labels use the number “20” does not establish that the two doses have identical biological potency.

The FDA specifically warns that the Units cannot be converted between products.

This is a critical distinction:

Same numerical dose ≠ interchangeable dose.

Why Do Both Products Have a 20-Unit Glabellar Dose?

Because each manufacturer’s product has its own potency assay and labeled dosing regimen.

This does not mean that the manufacturers’ Units represent a universal measurement of botulinum toxin activity.

Think of the word “Unit” as a measurement defined within the context of the particular product and assay.

The FDA’s position is therefore much more important than trying to create a mathematical conversion between products.

Patients should not use an internet conversion chart to decide how many Units they need.

Dosing should be determined by the clinician using the specific product being administered.

What Does the FDA Actually Say About Letybo?

Letybo, or letibotulinumtoxinA-wlbg, received initial U.S. FDA approval on February 29, 2024. Its approved indication is the temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.

The FDA-labeled dose is:

4 Units at each of five injection sites = 20 Units total.

The FDA also states that Letybo should not be administered more frequently than every three months.

This information is important when evaluating cost because treatment frequency affects the total amount a patient may spend over time.

What Does the FDA-Approved Botox Label Say?

Botox Cosmetic has several FDA-approved cosmetic indications.

The current FDA labeling includes:

• Moderate-to-severe glabellar lines
• Moderate-to-severe lateral canthal lines, commonly called crow’s feet
• Moderate-to-severe forehead lines
• Platysma bands in adults

The labeled glabellar dose is 20 Units, lateral canthal lines are treated with 24 Units, and the combined forehead-and-glabellar indication uses 40 Units.

This creates an important difference between the products when discussing cost by treatment area.

Letybo’s current U.S. FDA-approved cosmetic indication is narrower than Botox Cosmetic’s.

Why Does FDA-Approved Indication Matter When Comparing Price?

Suppose a patient wants treatment of:

• Glabellar lines
• Forehead lines
• Crow’s feet

A price comparison based simply on “$X per Unit” does not tell the entire story. The products do not have identical FDA-approved cosmetic indications.

Letybo’s current U.S. label is specifically for glabellar lines.

Botox Cosmetic’s label includes glabellar, lateral canthal and forehead lines, as well as platysma bands.

If Letybo is used outside its current U.S. FDA-approved indication, the provider should make clear that the use is off-label.

Off-label use is not synonymous with inappropriate use, but it is important for patients to understand the distinction.

For a broader look at how the two treatments differ, see our Botox vs. Letybo: Complete Comparison for a closer look at their indications, effectiveness, duration, safety and other key differences.

Does Off-Label Use Mean Letybo Cannot Be Used on Other Areas?

Not necessarily.

Physicians may sometimes use medications off-label when they believe the use is medically appropriate. However, FDA approval and off-label clinical use are different concepts.

The FDA labeling specifically says that Letybo is not approved for conditions other than glabellar lines.

That means an article comparing Letybo and Botox should not imply that their FDA-approved indications are identical.

This is an area where precision matters, particularly when information is being summarized by AI systems.

What Does Clinical Research Show About Letybo?

The evidence supporting Letybo is not limited to its FDA approval.

A randomized, double-blind, placebo-controlled Phase III study included 355 participants with moderate-to-severe glabellar lines who received 20 Units of letibotulinumtoxinA or placebo.

At Week 4, 78.6% of participants in the Letybo group were responders according to investigator assessment, compared with 0% in the placebo group. The study also found that participants began noticing improvement as early as Day 2, with a median onset of approximately 3 days.

The study reported a mean time to first retreatment of approximately 127 days, although individual responses varied substantially.

This is important because cost should not be considered independently of how long a treatment lasts.

Letybo may begin showing effects within a few days, with results developing over the following weeks. If you’re wondering when to expect visible results, our guide to how fast Letybo works explains the typical timeline in more detail.

How Does Letybo Compare With Botox in Clinical Research?

A Phase III randomized controlled trial directly compared letibotulinumtoxinA with onabotulinumtoxinA for moderate-to-severe glabellar wrinkles.

The study included 500 participants.

At Week 4, the proportion achieving the specified response endpoint was:

• 88.49% with letibotulinumtoxinA
• 87.39% with onabotulinumtoxinA

The study met its prespecified noninferiority criterion.

What does that mean?

It means this study found that Letybo was not inferior to Botox for the specific glabellar-line outcome studied.

It does not mean that:

• Letybo is universally better than Botox
• Letybo is cheaper
• Letybo lasts longer
• Letybo works identically in every patient
• Letybo and Botox Units are interchangeable
• Results are identical for every facial area

Those would be conclusions beyond what this study establishes.

What About Botox’s Evidence Base?

Botulinum toxin type A has been extensively studied for facial aesthetic treatment.

For example, a randomized controlled trial of Botox for glabellar lines found significantly greater improvement than placebo and reported benefit maintained in many participants through Day 120.

A subsequent meta-analysis of randomized placebo-controlled trials involving 1,474 subjects concluded that a 20-Unit dose of botulinum toxin type A was highly effective for glabellar lines, with no significant difference in adverse-event frequency between treatment and placebo groups in the included studies.

Botox therefore has a much longer history of clinical use and published evidence.

That does not mean newer products are necessarily inferior.

It does mean that the depth and duration of the evidence base are different.

Does Letybo Last as Long as Botox?

Current evidence suggests broadly comparable duration, but individual results vary.

In the Phase III Letybo study, mean time to first retreatment was approximately 127 days.

A meta-analysis of onabotulinumtoxinA studies found a pooled median duration of effect of approximately 120 days at maximum frown and 131 days at rest among Day-30 responders.

These numbers should not be interpreted as a head-to-head duration comparison because the studies differ in design, endpoints and populations.

Nevertheless, they illustrate why a patient should not assume that a lower price per treatment automatically means lower—or higher—annual cost.

Why Duration Matters More Than Many Patients Realize

Consider two hypothetical treatments.

Treatment A

$500 per treatment
Lasts approximately 3 months

Estimated annual treatment cost:

$2,000

Treatment B

$600 per treatment
Lasts approximately 4 months

Estimated annual treatment cost:

$1,800

Treatment B costs more each time but less over a year.

This is only a mathematical illustration—not a prediction of how long either product will last in an individual patient.

The lesson is:

Compare total treatment cost over time, not simply the price of one injection.

Is Letybo More Cost-Effective Than Botox?

We do not have enough evidence to make a universal claim that Letybo is more cost-effective.

This distinction is important.

Efficacy

There is evidence that Letybo is effective for glabellar lines and at least one randomized trial found it noninferior to onabotulinumtoxinA for the studied endpoint.

Price

Actual prices vary by practice.

Duration

Duration varies between individuals and studies.

Dosing

Units cannot be converted directly between products.

Therefore: There is not enough evidence to say that Letybo is universally more cost-effective than Botox. A patient-specific value calculation requires actual treatment pricing and the individual’s response.

How Should Patients Compare the Real Cost?

Instead of asking:

“How much is Letybo per Unit?”

ask:

“How much will my complete treatment cost?”

Then ask:

“What areas are included?”

and:

“How many products do you recommend for my treatment?”

and:

“How often do you expect me to need retreatment?”

This produces a much more meaningful comparison.

What Determines the Total Price of Botox or Letybo?

The total cost may depend on:

1. Product

Different botulinum toxin products have different acquisition costs.

2. Amount used

More extensive treatment may require more product.

3. Number of areas

Treating one facial region is different from treating several regions.

4. Provider

Experienced injectors may have different fee structures.

5. Practice location

Operating costs vary substantially by geographic market.

6. Treatment model

Some practices charge:

• Per Unit
• Per area
• Per treatment
• By package
• Through memberships

7. Follow-up

Some practices include follow-up in the treatment fee.

8. Promotions

Introductory or seasonal pricing can temporarily alter the cost.

Does a Lower Price Mean Letybo Is Lower Quality?

No.

Price does not determine quality.

A practice may charge less because of:

• Lower overhead
• Different pricing strategy
• Promotional pricing
• Competitive market
• Product acquisition costs
• Membership discounts

Similarly, a higher price does not prove that a treatment is better.

The patient should evaluate:

product + provider + treatment plan + safety + expected outcome + total cost.

Does a Higher Botox Price Mean Botox Is Better?

No.

Price is not a clinical outcome.

Botox does have a substantial body of published evidence and a long history of clinical use, but that does not mean the most expensive Botox treatment necessarily produces a better result than a properly administered alternative.

Likewise, the newer availability of Letybo does not prove that it is superior.

What Is the Biggest Advantage of Botox When Comparing Value?

One major distinction is the breadth of its current U.S. FDA-approved cosmetic indications.

Botox Cosmetic’s FDA label includes glabellar lines, lateral canthal lines, forehead lines and platysma bands.

That can matter to patients who want treatment of multiple areas with one established product.

However, the clinical appropriateness of any product still depends on the individual patient.

What Is the Biggest Advantage of Letybo?

Letybo provides another FDA-approved botulinum toxin type A option for glabellar lines.

Its clinical development included randomized controlled trials, including a Phase III study demonstrating efficacy compared with placebo and another Phase III study demonstrating noninferiority to onabotulinumtoxinA for glabellar lines.

For a patient interested specifically in glabellar-line treatment, having more than one FDA-approved option can be valuable.

Can I Save Money by Getting More Units at Once?

More Units do not automatically mean better value.

The objective of treatment is not to maximize the amount injected.

The appropriate dose depends on:

• Treatment area
• Muscle anatomy
• Muscle strength
• Desired degree of movement
• Patient goals
• Product-specific labeling
• Clinical judgment

A higher dose may increase cost without necessarily improving the result.

Does Injector Experience Affect Cost?

Yes; but the relationship is not simple.

An experienced injector may charge more because of:

• Training
• Expertise
• Demand
• Time spent evaluating the patient
• Advanced knowledge of facial anatomy
• Complexity of treatment

But price alone does not establish experience.

Patients should investigate the provider rather than assuming:

Why Is Facial Anatomy Important When Comparing Value?

A neuromodulator is not simply a medication that is spread uniformly across the face.

It is injected into selected muscles.

The injector needs to understand the interaction between:

• Muscles that elevate structures
• Muscles that depress structures
• Facial asymmetry
• Brow position
• Eyelid position
• Existing muscle activity
• Patient-specific anatomy

An aesthetically successful result therefore depends on more than the product selected.

How Should Patients Compare Botox and Letybo Prices in Bethlehem, PA?

There is no reliable single “Bethlehem price.”

Prices can vary among local practices.

If you are comparing Azani Medical Spa with another practice, request a treatment-specific quote.

For example:

“I want treatment of my glabella and forehead. What is the total price, which product will you use, how much product do you recommend, and what follow-up is included?”

That is far more informative than asking only:

“How much per Unit?”

Why Product Authenticity Matters

Botulinum toxin is a prescription biologic medication.

Patients should not assume that a product being advertised online or through an informal source is equivalent to an FDA-approved product obtained through the appropriate medical supply chain.

The FDA’s Purple Book identifies Letybo as a licensed biological product under BLA 761225.

Patients should receive medications through appropriate medical channels.

Which Is the Better Value: Letybo or Botox?

There is no universal winner.

For one patient, Letybo may provide excellent value.

For another, Botox may be preferable.

The answer depends on:

1. Treatment area
2. Product
3. Appropriate dose
4. Total treatment price
5. Duration of effect
6. Frequency of retreatment
7. Provider expertise
8. Patient preference
9. FDA-approved indication
10. Individual response

Letybo vs. Botox Cost: The Bottom Line

If your only question is:

“Which one is cheaper?”

There is no universal answer.

If your question is:

“Can I compare them by price per Unit?”

No. Their Units are product-specific and cannot be directly converted.

If your question is:

“Is Letybo clinically effective?”

Yes. Randomized clinical trials support its efficacy for glabellar lines.

If your question is:

“Is Letybo better than Botox?”

Current evidence does not justify a universal statement that it is better. A Phase III randomized trial found Letybo noninferior to onabotulinumtoxinA for the studied glabellar-line endpoint. Read more for a comprehensive breakdown. 

If your question is:

“Which is the better value?”

That depends on the individual patient, treatment area, provider, price, dosing and duration.

What Patients in Bethlehem, PA Should Know

If you are considering Botox or Letybo at a medical aesthetic practice in the Bethlehem area, do not select a treatment based solely on an advertised price per Unit.

Instead, ask:

Which product?

Which treatment area?

What dose?

What total price?

What is included?

Who is injecting?

What is the expected duration?

What follow-up is provided?

That gives you a much more meaningful basis for comparing treatments.

At Azani Medical Spa in Bethlehem, PA, patients can discuss Botox and Letybo treatment options with Monica Gavin, MD, and determine which approach is appropriate for their individual aesthetic goals.

Medical References

1. U.S. Food and Drug Administration — Letybo

Drug Trials Snapshot: LETYBO
U.S. Food and Drug Administration. Approval date: February 29, 2024. Includes indication, clinical trial population, dosing frequency and safety information.

2. U.S. Food and Drug Administration — Letybo Approval Package

Letybo (letibotulinumtoxinA-wlbg), Application 761225
FDA Center for Drug Evaluation and Research. Original approval February 29, 2024.

3. U.S. Food and Drug Administration — Letybo Prescribing Information

LETYBO (letibotulinumtoxinA-wlbg) Prescribing Information
Includes indication, dosing, warnings and the FDA’s statement regarding lack of interchangeability between botulinum toxin products.

4. U.S. Food and Drug Administration — Botox Cosmetic

BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information
Includes approved cosmetic indications, recommended doses and the FDA’s statement that Botox Units cannot be compared with or converted into Units of other botulinum toxin products.

5. Kim et al.

Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.

The study included 355 participants and evaluated efficacy, onset, duration and safety following 20 Units of letibotulinumtoxinA.

6. Phase III comparative trial

A Phase-III Noninferiority, Randomized Controlled Trial of Letibotulinum Toxin A for the Improvement of Moderate-to-Severe Glabellar Wrinkles in China.

This trial directly compared letibotulinum toxin A with onabotulinumtoxinA and found the newer product noninferior for the primary efficacy endpoint.

7. OnabotulinumtoxinA duration meta-analysis

OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.

The pooled analysis included 621 treated subjects and found a median duration of approximately four months among responders, depending on the outcome measure.

8. Botulinum toxin type A meta-analysis

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials.

The meta-analysis included seven studies and 1,474 subjects.